These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11595236)

  • 1. Identification and characterisation of Toxoplasma gondii protein farnesyltransferase.
    Ibrahim M; Azzouz N; Gerold P; Schwarz RT
    Int J Parasitol; 2001 Nov; 31(13):1489-97. PubMed ID: 11595236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboxy-terminal CFFL-sequence-specific monomeric protein geranylgeranyltransferase I from the eyes of the shrimp Penaeus japonicus.
    Lin RS; Chuang NN
    J Exp Zool; 1998 Aug; 281(6):565-73. PubMed ID: 9697321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the carboxyterminal residue in peptide binding to protein farnesyltransferase and protein geranylgeranyltransferase.
    Roskoski R; Ritchie P
    Arch Biochem Biophys; 1998 Aug; 356(2):167-76. PubMed ID: 9705207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein farnesyltransferase and protein prenylation in Plasmodium falciparum.
    Chakrabarti D; Da Silva T; Barger J; Paquette S; Patel H; Patterson S; Allen CM
    J Biol Chem; 2002 Nov; 277(44):42066-73. PubMed ID: 12194969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors.
    Del Villar K; Urano J; Guo L; Tamanoi F
    J Biol Chem; 1999 Sep; 274(38):27010-7. PubMed ID: 10480914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-dependent inhibition of protein farnesyltransferase by a benzodiazepine peptide mimetic.
    Roskoski R; Ritchie PA
    Biochemistry; 2001 Aug; 40(31):9329-35. PubMed ID: 11478901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrocyclic piperazinones as potent dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I.
    Dinsmore CJ; Zartman CB; Bergman JM; Abrams MT; Buser CA; Culberson JC; Davide JP; Ellis-Hutchings M; Fernandes C; Graham SL; Hartman GD; Huber HE; Lobell RB; Mosser SD; Robinson RG; Williams TM
    Bioorg Med Chem Lett; 2004 Feb; 14(3):639-43. PubMed ID: 14741259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion of Tyr361 beta to Leu in mammalian protein farnesyltransferase impairs product release but not substrate recognition.
    Spence RA; Hightower KE; Terry KL; Beese LS; Fierke CA; Casey PJ
    Biochemistry; 2000 Nov; 39(45):13651-9. PubMed ID: 11076503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-thiol farnesyltransferase inhibitors: utilization of an aryl binding site by 5-arylacryloylaminobenzophenones.
    Mitsch A; Böhm M; Wissner P; Sattler I; Schlitzer M
    Bioorg Med Chem; 2002 Aug; 10(8):2657-62. PubMed ID: 12057654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate characterization of the Saccharomyces cerevisiae protein farnesyltransferase and type-I protein geranylgeranyltransferase.
    Caplin BE; Hettich LA; Marshall MS
    Biochim Biophys Acta; 1994 Mar; 1205(1):39-48. PubMed ID: 8142482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of potent nonpeptidic farnesyltransferase inhibitors based on a terphenyl scaffold.
    Ohkanda J; Lockman JW; Kothare MA; Qian Y; Blaskovich MA; Sebti SM; Hamilton AD
    J Med Chem; 2002 Jan; 45(1):177-88. PubMed ID: 11754590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-peptidic, non-prenylic bisubstrate farnesyltransferase inhibitors. Part 3: structural requirements of the central moiety for farnesyltransferase inhibitory activity.
    Schlitzer M; Böhm M; Sattler I
    Bioorg Med Chem; 2000 Oct; 8(10):2399-406. PubMed ID: 11058034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of tripeptidyl farnesyltransferase inhibitors.
    Lee HY; Sohn JH; Kwon BM
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1599-602. PubMed ID: 12039571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the development of farnesyltransferase inhibitors: substrate recognition by protein farnesyltransferase.
    Yang W; Del Villar K; Urano J; Mitsuzawa H; Tamanoi F
    J Cell Biochem Suppl; 1997; 27():12-9. PubMed ID: 9591188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H-Ras peptide and protein substrates bind protein farnesyltransferase as an ionized thiolate.
    Hightower KE; Huang CC; Casey PJ; Fierke CA
    Biochemistry; 1998 Nov; 37(44):15555-62. PubMed ID: 9799520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I.
    Qiao Y; Gao J; Qiu Y; Wu L; Guo F; Lo KK; Li D
    Eur J Med Chem; 2011 Jun; 46(6):2264-73. PubMed ID: 21440964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein prenyl transferase activities of Plasmodium falciparum.
    Chakrabarti D; Azam T; DelVecchio C; Qiu L; Park YI; Allen CM
    Mol Biochem Parasitol; 1998 Aug; 94(2):175-84. PubMed ID: 9747968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic studies of rat protein farnesyltransferase indicate an associative transition state.
    Huang C; Hightower KE; Fierke CA
    Biochemistry; 2000 Mar; 39(10):2593-602. PubMed ID: 10704208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
    Tamanoi F; Gau CL; Jiang C; Edamatsu H; Kato-Stankiewicz J
    Cell Mol Life Sci; 2001 Oct; 58(11):1636-49. PubMed ID: 11706990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
    Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
    Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.